Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PRE Stock Forecast 2025-2026
$5.39
Current Price
$71.04M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PRE Price Targets
+141.3%
To High Target of $13.00
+141.3%
To Median Target of $13.00
+141.3%
To Low Target of $13.00
PRE Price Momentum
+1.3%
1 Week Change
+49.7%
1 Month Change
-9.0%
1 Year Change
-7.1%
Year-to-Date Change
-22.9%
From 52W High of $6.99
+74.1%
From 52W Low of $3.10
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Prenetics (PRE) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PRE and similar high-potential opportunities.
Latest PRE Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, PRE has a bullish consensus with a median price target of $13.00 (ranging from $13.00 to $13.00). Currently trading at $5.39, the median forecast implies a 141.3% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PRE Analyst Ratings
1
Buy
0
Hold
0
Sell
PRE Price Target Range
Low
$13.00
Average
$13.00
High
$13.00
Current: $5.39
Latest PRE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PRE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 16, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $9.00 |
| Dec 4, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $9.00 |
| Apr 4, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $9.00 |
| Sep 26, 2023 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $4.00 |
| Sep 19, 2023 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $4.00 |
| Aug 22, 2023 | Cantor Fitzgerald | Overweight | Reiterates | $0.00 | |
| Jan 18, 2023 | Cantor Fitzgerald | Ross Osborn | Overweight | Initiates | $7.00 |
| Jul 28, 2015 | Barclays | Overweight | Maintains | $140.00 | |
| Jul 9, 2015 | Deutsche Bank | Hold | Maintains | $6.10 | |
| Jun 18, 2015 | Keefe, Bruyette & Woods | Market Perform | Maintains | $140.00 | |
| May 13, 2015 | BMO Capital | Market Perform | Maintains | $137.50 | |
| May 6, 2015 | Deutsche Bank | Hold | Maintains | $6.50 | |
| Apr 22, 2015 | UBS | Neutral | Downgrade | $0.00 | |
| Apr 20, 2015 | Deutsche Bank | Hold | Maintains | $130.00 | |
| Apr 17, 2015 | BMO Capital | Market Perform | Downgrade | $130.00 | |
| Mar 26, 2015 | BMO Capital | Outperform | Upgrade | $122.00 | |
| Feb 5, 2015 | JMP Securities | Market Perform | Downgrade | $0.00 | |
| Jan 20, 2015 | Deutsche Bank | Hold | Maintains | $6.10 | |
| Jan 8, 2015 | Barclays | Overweight | Maintains | $125.00 | |
| Dec 9, 2014 | JP Morgan | Neutral | Initiates | $0.00 |
Prenetics Global Limited (PRE) Competitors
The following stocks are similar to Prenetics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Prenetics Global Limited (PRE) Financial Data
Prenetics Global Limited has a market capitalization of $71.04M with a P/E ratio of 1.1x. The company generates $30.62M in trailing twelve-month revenue with a -151.2% profit margin.
Revenue growth is +98.7% quarter-over-quarter, while maintaining an operating margin of -158.0% and return on equity of -26.1%.
Valuation Metrics
Market Cap
$71.04M
Enterprise Value
$3.33M
P/E Ratio
1.1x
PEG Ratio
-9.7x
Price/Sales
2.3x
Growth & Margins
Revenue Growth (YoY)
+98.7%
Gross Margin
+37.2%
Operating Margin
-158.0%
Net Margin
-151.2%
EPS Growth
+98.8%
Financial Health
Cash/Price Ratio
+101.2%
Current Ratio
2.4x
Debt/Equity
3.4x
ROE
-26.1%
ROA
-12.9%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Prenetics Global Limited (PRE) Business Model
About Prenetics Global Limited
What They Do
Biotechnology company specializing in genetic testing.
Business Model
Prenetics Global Limited generates revenue through its genetic and diagnostic testing services. By offering personalized health solutions and rapidly accessible testing kits, the company taps into both individual consumers and businesses within the healthcare sector. Their focus on precision medicine allows them to cater to a growing demand for reliable health data, thus creating multiple streams of income.
Additional Information
Headquartered in Hong Kong, Prenetics operates globally and emphasizes innovation and strategic partnerships to enhance its market position. The company's offerings address critical health needs and adapt to emerging public health challenges, making it a significant player in the biotechnology and healthcare sectors.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
285
CEO
Mr. Sheng Wu Yeung
Country
Hong Kong
IPO Year
2022
Website
www.prenetics.comPrenetics Global Limited (PRE) Latest News & Analysis
Latest News
Quick Summary
Two renowned clinical experts, Dr. Jeremy London and Dr. Amy Shah, are joining a team with backgrounds from prestigious institutions like Mayo Clinic and Yale University.
Why It Matters
The addition of renowned clinical experts enhances the company's credibility and innovation potential, likely boosting investor confidence and market value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Prenetics Announces Fourth Quarter and Full Year 2024 Financial Results, Provides 2025 Guidance
2 months ago
Quick Summary
Revenue increased 93.5% to $10.5 million in Q4 and 40.9% year-over-year to $30.6 million for 2024.
Why It Matters
Strong revenue growth signals robust company performance, likely boosting investor confidence and potential stock appreciation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Prenetics Global Limited (NASDAQ: PRE) has announced a partnership with Humanity Protocol to use its genetic testing for decentralized identity verification, enhancing its service offerings.
Why It Matters
Prenetics' partnership with Humanity Protocol enhances its market position, potentially boosting revenue and attracting investment in the growing genomics and blockchain sectors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Prenetics' IM8 Achieves Prestigious NSF Certified for Sport® for Daily Ultimate Essentials
3 months ago
Quick Summary
David Beckham co-founded the premium supplements brand IM8, which offers NSF Certified for Sport® products. IM8 ships to 31 regions and is trusted by elite athletes across various sports.
Why It Matters
The certification of IM8's product enhances brand credibility, attracting health-conscious consumers and athletes, potentially boosting sales and market share in a competitive supplements industry.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Prenetics' IM8 has launched a month-long space experiment aboard the ISS, in partnership with the University of Oxford, to study accelerated aging in microgravity, following its launch on November 4.
Why It Matters
The experiment's focus on accelerated aging and longevity in space could lead to breakthroughs in healthcare, potentially driving innovation and investment in biotechnology and related sectors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Prenetics Global Limited (NASDAQ: PRE) will have its management team participate in two upcoming investor conferences, enhancing visibility for the company.
Why It Matters
Management participation in investor conferences signals transparency and potential growth opportunities, which can influence investor confidence and stock price movements.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PRE Stock
What is Prenetics Global Limited's (PRE) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Prenetics Global Limited (PRE) has a median price target of $13.00. The highest price target is $13.00 and the lowest is $13.00.
Is PRE stock a good investment in 2025?
According to current analyst ratings, PRE has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.39. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PRE stock?
Wall Street analysts predict PRE stock could reach $13.00 in the next 12 months. This represents a 141.3% increase from the current price of $5.39. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Prenetics Global Limited's business model?
Prenetics Global Limited generates revenue through its genetic and diagnostic testing services. By offering personalized health solutions and rapidly accessible testing kits, the company taps into both individual consumers and businesses within the healthcare sector. Their focus on precision medicine allows them to cater to a growing demand for reliable health data, thus creating multiple streams of income.
What is the highest forecasted price for PRE Prenetics Global Limited?
The highest price target for PRE is $13.00 from at , which represents a 141.3% increase from the current price of $5.39.
What is the lowest forecasted price for PRE Prenetics Global Limited?
The lowest price target for PRE is $13.00 from at , which represents a 141.3% increase from the current price of $5.39.
What is the overall PRE consensus from analysts for Prenetics Global Limited?
The overall analyst consensus for PRE is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $13.00.
How accurate are PRE stock price projections?
Stock price projections, including those for Prenetics Global Limited, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2025 8:22 AM UTC